Yonsa is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed from 2018 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 20, 2034. Details of Yonsa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10292990 | Abiraterone steroid formulation |
May, 2034
(7 years from now) | Active |
| US9889144 | Abiraterone acetate formulation and methods of use |
Mar, 2034
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Yonsa's patents.
Latest Legal Activities on Yonsa's Patents
Given below is the list of recent legal activities going on the following patents of Yonsa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Aug, 2025 | US9889144 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Nov, 2022 | US10292990 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Aug, 2021 | US9889144 |
| Recordation of Patent Grant Mailed
Critical | 21 May, 2019 | US10292990 |
| Patent Issue Date Used in PTA Calculation
Critical | 21 May, 2019 | US10292990 |
| Email Notification
Critical | 02 May, 2019 | US10292990 |
| Issue Notification Mailed
Critical | 01 May, 2019 | US10292990 |
| Dispatch to FDC | 02 Apr, 2019 | US10292990 |
| Application Is Considered Ready for Issue
Critical | 02 Apr, 2019 | US10292990 |
| Issue Fee Payment Verified
Critical | 29 Mar, 2019 | US10292990 |
US patents provide insights into the exclusivity only within the United States, but
Yonsa is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Yonsa's family patents as well as insights into
ongoing legal events
on those patents.
Yonsa's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Yonsa:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Yonsa's generic launch date based on the expiry of its last outstanding patent is estimated to be May 20, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yonsa Generic API suppliers:
Abiraterone Acetate is the generic name for the brand Yonsa. 13 different companies have already filed for the generic of Yonsa, with Teva Pharms Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Yonsa's generic
How can I launch a generic of Yonsa before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Yonsa's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Yonsa's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Yonsa -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 23 Jul, 2018 | 17 Mar, 2034 | Deferred | 24 Jun, 2022 | Less |
Alternative Brands for Yonsa
Yonsa which is used for treating prostate cancer in combination with methylprednisolone., has several other brand drugs using the same active ingredient (Abiraterone Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Abiraterone Acetate, Yonsa's active ingredient. Check the complete list of approved generic manufacturers for Yonsa
About Yonsa
Yonsa is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for treating prostate cancer in combination with methylprednisolone. Yonsa uses Abiraterone Acetate as an active ingredient. Yonsa was launched by Sun Pharma in 2018.
Approval Date:
Yonsa was approved by FDA for market use on 22 May, 2018.
Active Ingredient:
Yonsa uses Abiraterone Acetate as the active ingredient. Check out other Drugs and Companies using Abiraterone Acetate ingredient
Treatment:
Yonsa is used for treating prostate cancer in combination with methylprednisolone.
Dosage:
Yonsa is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 125MG | TABLET | Prescription | ORAL |